StockData
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. (NVCT) stock

NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.11−1.13 (-5.58%)

Close on Nov 16, 2026Market cap $622.63MP/E –Yield 0.00%

Nuvectis Pharma cash

Cash and short-term investments held at the end of each period.

Nuvectis Pharma's cash was $22.16M at Jun 30, 2026. For fiscal 2025 it was $31.63M, up 70.7% from the year before. The highest annual figure on record is $31.63M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$31.63M+70.7%
FY2024Dec 31, 2024$18.53M-3.1%
FY2023Dec 31, 2023$19.13M-4.3%
FY2022Dec 31, 2022$19.99M+248.2%
FY2021Dec 31, 2021$5.74M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.16M-17.3%
Q1 FY2026Mar 31, 2026$25.13M-15.9%
Q4 FY2025Dec 31, 2025$31.63M+70.7%
Q3 FY2025Sep 30, 2025$35.44M+106.4%
Q2 FY2025Jun 30, 2025$26.79M+47.9%
Q1 FY2025Mar 31, 2025$29.86M+53.4%
Q4 FY2024Dec 31, 2024$18.53M-3.1%
Q3 FY2024Sep 30, 2024$17.17M-22.2%
Q2 FY2024Jun 30, 2024$18.12M-26.4%
Q1 FY2024Mar 31, 2024$19.46M+25.8%
Q4 FY2023Dec 31, 2023$19.13M-4.3%
Q3 FY2023Sep 30, 2023$22.06M-6.7%
Q2 FY2023Jun 30, 2023$24.60M+81.3%
Q1 FY2023Mar 31, 2023$15.47M-7.3%
Q4 FY2022Dec 31, 2022$19.99M+248.2%
Q3 FY2022Sep 30, 2022$23.64M+247.2%
Q2 FY2022Jun 30, 2022$13.57M+88.1%
Q1 FY2022Mar 31, 2022$16.69M–
Q4 FY2021Dec 31, 2021$5.74M–
Q3 FY2021Sep 30, 2021$6.81M–
Q2 FY2021Jun 30, 2021$7.21M–

More Nuvectis Pharma figures

See a number that looks wrong?